Evaluation of treatment satisfaction after switching to delgocitinib ointment for trunk and limbs rash in atopic dermatitis.
- Conditions
- Atopic dermatitis
- Registration Number
- JPRN-jRCTs031230102
- Lead Sponsor
- Abe Masatoshi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 100
(1) Patients aged 18 years and older with atopic dermatitis when obtaining consent.
(2) Patients using topical steroids for trunk or limb rash for more than 3 months.
(3) Patients with local side effects such as skin atrophy or telangiectasia due to the use of topical steroids on the trunk or limb or who are expected to use topical steroids for a long time and are concerned about the development of local side effects.
(4) Patients whose trunk and limbs are being treated with topical steroids and are considered treatable with a maximum of 5 g of delgocitinib ointment per dose (within approximately 30% of body surface area, taking into account body size).
(5) Patients who have given written consent to participate in the study.
**: Any rank and formulation of topical steroids.
(1) Patients using the strongest topical steroids. Using clobetasol propionate shampoo on the scalp is allowed.
(2) Patients using delgocitinib ointment or difamilast ointment.
(3) Patients with plaque or other erosions forming obvious foci at the site of application of studied drug.
(4) Patients who are pregnant, may become pregnant, or plan to become pregnant during the study period.
(5) Patients who are breastfeeding
(6) Patients previously treated with delgocitinib ointment
(7) Patients receiving systemic therapy with internal medications (steroids, cyclosporine, JAK inhibitors) at the time of obtaining consent or within the last 3 months.
(8) Patients receiving systemic therapy with biologics (e.g., dupilumab, nemolizumab) at the time of obtaining consent or within the last 6 months
(9) Patients receiving phototherapy, such as ultraviolet light therapy, at the time of obtaining consent or within the last 3 months.
(10) Patients who have participated in a clinical trial or similar within the last 6 months
(11) Patients deemed ineligible for the study by the investigator or others.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method